Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103(9):1243–1252.
Abrams, J. R., Kelley, S. L., Hayes, E., et al. (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J. Exp. Med. 192(5):681–694.
Ahrens, N., Salama, A., Haas, J. (2001). Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J. Neurol. 248(8):713–714.
Aktas, O., Waiczies, S., Smorodchenko, A., et al. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 17;197(6):725–733.
Alegre, M. L., Sattar, H. A., Herold, K. C., et al. (1994) Prevention of the humoral response induced by an anti-CD3 monoclonal antibody by deoxyspergualin in a murine model. Transplantation 57(12):1786–1794.
Aloisi, F., Penna, G., Polazzi, E., et al. (1999) CD40-CD154 interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells. J. Immunol. 162(3):1384–1391.
Andersen, O., Lycke, J., Tollesson, P. O. (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47:895–900.
Anderson, D. E., Sharpe, A. H., Hafler, D. A. (1999) The B7-CD28/CTLA-4 costimulatory pathways in autoimmune disease of the central nervous system. Curr. Opin. Immunol. 11(6):677–683.
Anderson, D. E., Bieganowska, K. D., Bar-Or, A., et al. (2000) Paradoxical inhibition of T-cell function in response to CTLA-4 blockade; heterogeneity within the human T-cell population. Nat. Med. 6(2):211–214.
Anonymous. (2004) Drugs RD 5(6):363–367.
Archelos, J. J., Hartung, H. P. (2000) Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 23:317–327.
Archelos, J. J., Previtali, S. C., Hartung, H. P. (1999) The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. 22(1):30–38.
Archelos, J. J., Storch, M. K., Hartung, H. P. (2000) The role of B cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47(6):694–706.
Arroyo, A. G., Yang, J. T., Rayburn, H., Hynes, R. O. (1996) Differential requirements for alpha4 integrins during fetal and adult hematopoiesis. Cell 85(7):997–1008.
Babbe H., Roers A. Waisman A. (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 1192:393–404.
Baecher-Allan, C., Hafler, D. A. (2004) Suppressor T cells in human diseases. J. Exp. Med. 200(3):273–276.
Baggiolini, M. (1998) Chemokines and leukocyte traffic. Nature 392(6676):565–568.
Bar-Or, A., Antel, J., Bodner, C. A. (2006) Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Neurology 66(Suppl.):A62.
Beggiolin, G., Crippa, L., Menta, E., et al. (2001) Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 87(6):407–416.
Benoist, C., Mathis, D. (2001) Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2:797–801.
Bernitsas, E., Wei, W., Mikol, D. D. (2006) Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. Ann. Neurol. 59(1):206–209.
Beutler, E. (1992) Cladribine (2-chlorodeoxyadenosine). Lancet 340(8825):952–956.
Beutler, E., Sipe, J. C., Romine, J. S., et al. (1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl. Acad. Sci. U S A 93(4):1716–1720.
Bielekova, B., Goodwin, B., Richert, N., et al. (2000a) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6(10):1167–1175.
Bielekova, B., Lincoln, A., McFarland, H., Martin, R. (2000b) Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol. 164(2):1117–1124.
Bielekova, B., Richert, N., Howard, T., et al. (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. U S A. 101(23):8705–8708.
Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., et al. (2006) Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R{alpha}-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U S A. 103(15):5941–5946.
Birnbaum, G., Altafullah, I. (2005) Neurology 64(Suppl. 1):A385, P06.158.
Bisikirska, B., Colgan, J., Luban, J., et al. (2005) TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 115(10):2904–2913.
Bjartmar, C., Trapp, B. D. (2001) Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14:271–278.
Bluestone, J. A., St. Clair, E. W., Turka, L. A. (2006) CTLA4Ig: bridging the basic immunology with clinical application. Immunit. 24(3):233–238.
Bowen, J. D., Petersdorf, S. H., Richards, T. L., et al. (1998) Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. Clin. Pharmacol. Ther. 64(3):339–346.
Brassat, D., Recher, C., Waubant, E., et al. (2002) Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 59(6):954–955.
Brinkmann, V., Davis, M. D., Heise, C. E., et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277(24):21453–21457.
Bruck, W., Neubert, K., Berger, T., Weber, J. R. (2001) Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination—possible markers for an antibody-mediated process. Mult. Scler. 7(3):173–177.
Brundula, V., Rewcastle, N. B., Metz, L. M., et al. (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125(Pt 6):1297–1308.
Brunmark, C., Runstrom, A., Ohlsson, L., et al. (2002) The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 130(1–2):163–172.
Budde K., Schmouder R. L., Brunkhorst R., et al. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13(4):1073–1083.
Calabresi, P. A., Wilterdink, J. L., Rogg, J. M., et al. (2002) An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58(2):314–317.
Canadian Cooperative Multiple Sclerosis Study Group. (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337(8739):441–446.
Carreno, B. M., Collins, M. (2002) The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:29–53.
Cavaletti, G., Cavalletti, E., Crippa, L., et al. (2004) Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. J. Neuroimmunol. 151(1–2):55–65.
Charo, I. F., Ransohoff, R. M. (2006) The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354(6):610–621.
Chatenoud, L. (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3(2):123–132.
Chen, B. J., Morris, R. E., Chao, N. J. (2000) Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol. Blood Marrow Transplant. 6(5A):529–536.
Chiba, K. (2005) FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108(3):308–319.
Clements, J. M., Cossins, J. A., Wells, G. M., et al. (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 74(1–2):85–94.
Cohen, B. A., Mikol, D. D. (2004) Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 63(Suppl. 6):S28–S32.
Coles, A. J., Wing, M. G., Molyneux, P., et al. (1999a) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46(3):296–304.
Coles, A. J., Wing, M., Smith, S., et al. (1999b) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354(9191):1691–1695.
Columba-Cabezas, S., Serafini, B., Ambrosini, E., et al. (2002) Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J. Neuroimmunol. 130(1–2):10–21.
Cyster, J. G. (2005) Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. 23:127–159.
Dello Russo, C., Gavrilyuk, V., Weinberg, G., et al. (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J. Biol. Chem. 278(8):5828–5836.
Diab, A., Deng, C., Smith, J. D., et al. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-delta(12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168(5):2508–2515.
Dinter, H., Tse, J., Halks-Miller, M., Asarnow, D., et al. (2004) The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J. Neuroimmunol. 108(1–2):136–146.
Dormandy, J. A., Charbonnel, B., Eckland, D. J., et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289.
Ducray, F., Vukusic, S., Gignoux, L. (2004) Mycophenolate mofetil: an open-label study in 42 MS patients. Mult. Scler. 10(Suppl.):S263–S263.
Dunn, S. E., Youssef, S., Goldstein, M. J., et al. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 203:401–412.
Dyke, H. J., Montana, J. G. (2002) Update on the therapeutic potential of PDE4 inhibitors. Expert Opin. Invest. Drugs. 11(1):1–13.
Edan, G. (2005) Immunosuppressive therapy in multiple sclerosis. Neurol. Sci. 26(Suppl.) 1:S18.
Edan, G., Miller, D., Clanet, M., et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry 62(2):112–118.
Elices, M. J. (2003) Natalizumab: Elan/Biogen. Curr. Opin. Invest. Drugs 4(11):1354–1362.
Engelhardt, B., Ransohoff, R. M. (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 26(9):485–495.
Faria, A. M., Weiner, H. L. (2005) Oral tolerance. Immunol. Rev. 206:232–259.
Farrell, R., Heaney, D., Giovannoni, G., (2005) Emerging therapies in multiple sclerosis. [Review] Expert. Opin. Emerg. Drugs 10(4):797–816.
Feinstein, D. L., Galea, E., Gavrilyuk, V., et al. (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51(6):694–702.
Feng, J., Misu, T., Fujihara, K., et al. (2004) Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis. Mult. Scler. 10(5):494–498.
Fernandez, O., Guerrero, M., Mayorga, C., et al. (2002) Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis: a two-year pilot study. J. Neurol. 249(8):1058–1062.
Filippi, M., Rovaris, M., Rice, G. P., et al. (2000a) The effect of cladribine on T(1) ‘black hole’ changes in progressive MS. J. Neurol Sci. 176(1):42–44.
Filippi, M., Rovaris, M., Iannucci, G., et al. (2000b) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 12;55(11):1714–1718.
Fontoura, P., Garren, H., Steinman, L. (2005) Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int. Rev. Immunol. 24(5–6):415–446.
Fox, R. J., Ransohoff, R. M. (2004) New directions in MS therapeutics: vehicles of hope. Trends Immunol. 25(12):632–636.
Francis, G., Evans, A., Panitch, H. (1997) MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann. Neurol. 42:467.
Frauwirth, K. A., Thompson, C. B. (2002) Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109(3):295–299.
Frohman, E. M., Brannon, K., Racke, M. K., Hawker, K. (2004) Mycophenolate mofetil in multiple sclerosis. Clin. Neuropharmacol. 27(2):80–83.
Frohman, E. M., Racke, M. K., Raine, C. S. (2006) Multiple sclerosis—the plaque and its pathogenesis. N. Engl. J. Med. 354(9):942–955.
Fujimoto, T., Sakoda, S., Fujimura, H., Yanagihara, T. (1999) Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J. Neuroimmunol. 95(1–2):35–42.
Fujino, M., Funeshima, N., Kitazawa, Y., et al. (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305(1):70–77.
Gaupp, S., Pitt, D., Kuziel, W. A., et al. (2003) Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains. Am. J. Pathol. 162(1):139–150.
Gauthier, S. A., Buckle, G. J., Weiner, H. L. (2005) Immunosuppressive therapy for multiple sclerosis. Neurol. Clin. 23(1):247–272, viii-ix.
Genovese, M. C., Becker, J. C., Schiff, M., et al. (2005) Abatacept for rheumatoid athritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11):1114–1123.
Germain, R. N., Stefanova, I. (1999) The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 17:467–522.
Ghalie, R. G., Mauch, E., Edan, G., et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. Scler. 8(5):441–445.
Giuliani, F., Fu, S. A., Metz, L. M., Yong, V. W. (2005a) Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J. Neuroimmunol. 165(1–2):83–91.
Giuliani, F., Metz, L. M., Wilson, T., et al. (2005b) Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158(1–2):213–221.
Gonsette, R. E. (2004) New immunosuppressants with potential implication in multiple sclerosis. J. Neurol. Sci. 223(1):87–93.
Gonsette, R. E., Dubois, B. (2004) Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J. Neurol. Sci. 223(1):81–86. Erratum in: J. Neurol. Sci. 2005;235(1–2):79.
Goodin, D. S., Frohman, E. M., Garmany, G. P., Jr., et al. (2002) Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2):169–178.
Goodkin, D. E., Rudick, R. A., VanderBrug Medendorp, S., et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 37(1):30–40.
Goodkin, D. E., Shulman, M., Winkelhake, J., et al. (2000) A phase I trial of solubilized DR2:MBP84–102 (AG284) in multiple sclerosis. Neurology 54(7):1414–1420.
Gordon, E. J., Myers, K. J., Dougherty, J. P., et al. (1995) Both anti-CD IIa (LFA-1) and anti-CD IIb (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 62(2):153–160.
Grillo-Lopez, A. J. (2005). 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin’s lymphoma. Semin. Oncol. 32(Suppl. 1):S44–S49.
Haas, J., Hug, A., Viehover, A., et al. (2005) Reduced suppressive effect of CD4+CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35(11):3343–3352.
Hafler, D. A., Slavik, J. M., Anderson, D. E., et al. (2005) Multiple sclerosis. Immunol. Rev. 204:208–231.
Hartung, H. P., Kieseier, B. C. (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107(2):140–147.
Hartung, H. P., Gonsette, R., König, N., et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018–2025.
Hauser, S. L., Hauser, S. L., Dawson, D. M., et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N. Engl. J. Med. 308(4):173–180.
He, K, Zeng, L, Shi, G, et al. (1997) Bioactive compounds from Taiwania cryptomerioides. J. Nat. Prod. 60(1):38–40.
Hemmer, B., Archelos, J. J., Hartung, H. P. (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3(4):291–301.
Hohlfeld, R. (1997) Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 120:865–916.
Hohlfeld, R, Wekerle, H. (2004) Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U S A 101(Suppl. 2):14599–14606.
Hohlfeld, R., Wekerle, H. (2005) Drug insight: using monoclonal antibodies to treat multiple sclerosis: Nature Clinical Practice. Neurology 1:34–44.
Hohlfeld, R., Wiendl, H. (2001) The ups and downs of multiple sclerosis therapeutics. Ann. Neurol. 49:281–284.
Howard, L. M., Miga, A. J., Vanderlugt, C. L., et al. (1999) Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103(2):281–290.
Howard, L. M., Kohm, A. P., Castaneda, C. L., Miller S. D. (2005) Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease. Curr. Drug Targets Inflamm. Allergy 4(2):205–216.
Huston, J. S., George, A. J. (2001) Engineered antibodies take center stage. Hum. Antibodies 10(3–4):127–142.
Jeffery, D. R. (2004) Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis. Neurology. 63(Suppl. 6):S41–S46.
Jönsson, S., Andersson, G., Fex, T., et al. (2004) Synthesis and biological evaluation of new 1, 2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J. Med. Chem. 47(8):2075–2088.
Jung, S., Zielasek, J., Kollner, G., et al. (1996) Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68(1–2):1–11.
Kappos, L., Patzold, U., Dommasch, D., et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis—results of the German multicenter study. Ann. Neurol. 23(1):56–63.
Kappos, L., Comi, G., Panitch, H., et al. (2000). Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial: the Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6(10):1176–1182.
Kappos, L., Radu, E. W., Antel, J., et al. (2005a) Promising results with a novel oral immunomodulator-FTY720-in relapsing multiple sclerosis. Mult. Scler. 11(Suppl.): S13.
Kappos, L., Barkhof, F., Desmet, A. (2005b) The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J. Neurol. 252(Suppl. 2):46.
Kappos, L., Antel, J., Comi, G., et al. (2006) Oral fingolimod (FTY720) for releasing multiple sclerosis. N. Engl. J. Med. 355(11):1124–1140.
Karussis, D. M., Meiner, Z., Lehmann, D., et al. (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47(2):341–346.
Kawai, T., Andrews, D., Colvin, R. B., et al. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6(2):114.
Keegan, M., Pineda, A. A., McClelland, R. L., et al. (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58(1):143–146.
Keegan, M., Konig, F., McClelland, R., et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366(9485):579–582.
Keeley, K. A., Rivey, M. P., Allington, D. R. (2005) Natalizumab for the treatment of multiple sclerosis and Crohn’s disease. Ann. Pharmacother. 39(11):1833–1843.
Keir, M. E., Sharpe, A. H. (2005) The B7/CD28 costimulatory family in autoimmunity. Immunol. Rev. 204:128–143.
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352(25):2598–2608.
Kieseier, B. C., Kiefer, R., Clements, J. M., et al. (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121(Pt 1):159–166.
Kieseier, B. C., Seifert, T., Giovannoni, G., Hartung, H. P. (1999) Matrix metallo-proteinases in inflammatory demyelination: targets for treatment. Neurology 53(1):20–25.
Khoury, J., Viglietta, V., Buckle, G., et al. (2005) Neurology 64(Suppl. 1):A393, S46.004.
Kim, K. S., Jacob, N., Stohl, W. (2003) In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens. Clin. Immunol. 108(3):182–189.
Kleinschmidt-DeMasters, B. K., Tyler, K. L. (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353(4):369–374.
Klotz, L., Schmidt, M., Giese, T., et al. (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 175(8):4948–4955.
Kobata, T., Azuma, M., Yagita, H., Okumura, K. (2000) Role of costimulatory molecules in autoimmunity. Rev. Immunogenet. 2(1):74–80.
Kohm, A. P., Williams, J. S., Bickford, A. L., et al. (2005) Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol. 174(8):4525–4534.
Korn, T., Toyka K., Hartung, H. P., Jung, S. (2001) Suppression of experimental autoimmune neuritis by leflunomide. Brain 124(Pt 9):1791–1802.
Korn, T., Magnus, T., Toyka, K., Jung, S. (2004) Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide—mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. 76(5):950–960.
Kwak, B., Mulhaupt, F., Myit, S., Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6(12):1399–1402.
Lang, H. L., Jacobsen, H., Ikemizu, S. (2002) Nat. Immunol. 3:940–943.
Langer-Gould, A., Atlas, S. W., Green, A. J., et al. (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353(4):375–381.
Larsen, C. P., Knechtle, S. J., Adams, A., et al. (2006) A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am. J. Transplant. 6(5):876–883.
Lassmann, H., Bruck, W., Lucchinetti, C. (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med. 14:259–269.
Lebwohl, M., Tyring, S. K., Hamilton, T. K., et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349(21):2004–2013.
Lennon, V. A., Kryzer, T. J., Pittock, S. J., et al. (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202(4):473–477.
Li, B., Wang, H., Dai, J., et al. (2005) Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116(4):487–498.
Likosky, W. H., Fireman, B., Elmore, R., et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J. Neurol. Neurosurg. Psychiatry. 54(12):1055–1060.
Lindberg, R. L., De Groot, C. J., Montagne, L., et al. (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124(Pt 9):1743–1753.
Lindsey, J. W., Hodgkinson, S., Mehta, R., et al. (1994a) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36(2):183–189.
Lindsey, J. W., Hodgkinson, S., Mehta, R., et al. (1994b) Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 44(Pt 1):413–419.
Linsley, P. S., Brady, W., Urnes, M., et al. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174(3):561–569.
Llewellyn-Smith, N., Lai, M., Miller, D. H., et al. (1997) Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology 48(4):810–816.
Lovett-Racke, A. E., Bittner, P., Cross, A. H., et al. (1998) Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J. Clin. Invest. 101(8):1797–1804.
Lovett-Racke, A. E., Hussain, R. Z., Northrop, S., et al. (2004) Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172(9):5790–5798.
Lublin, F., et al. (1999) A phase II trial of anti-CD11/CD18 monoclonal antibody in acute exacerbations of MS [abstract 290]. Neurology 52, Suppl 2.
Lucchinetti, C., Bruck, W., Parisi, J., et al. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6):707–717.
Lucchinetti, C. F., Mandler, R. N., McGavern, D., et al. (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125(Pt 7):1450–1461.
Lus, G., Romano, F., Scuotto, A., et al. (2004) Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur. Neurol. 51(1):15–20.
Maeda, A., Sobel, R. A. (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55(3):300–309.
Mandala, S., Hajdo, R., Bergstrom, J., et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296(5566): 346–349.
Marecki, S., Kirkpatrick, P. (2004) Efalizumab. Nat. Rev. Drug Discov. 3(6):473–474.
Markovic-Plese, S., Bielekova, B., Kadom, N., et al. (2003) Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology 60(11):1849–1851.
Marracci, G. H., McKeon, G. P., Marquardt, W. E., et al. (2004) Alpha lipoic acid inhibits human T-cell migration: implications for multiple sclerosis. J. Neurosci. Res. 78(3):362–370.
Marracci, G. H., Shinto, L., Strehlow, A., et al. (2005) Effect of omega-3 fatty acid supplementation on matrix metalloproteinase-9 production in multiple sclerosis. Neurology 64(Suppl. 1):A192–A193, P03.119.
Massacesi, L., Parigi, A., Barilaro, A., et al. (2005) Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging. Arch Neurol. 62(12):1843–7.
Matloubian, M., Lo, C.G., Cinamon, G., et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 427(6972):355–60.
Maurer, M., Loserth S., Kolb-Maurer A., et al. (2002) A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics. 54(1):1–8. Epub 2002 Mar 12.
Meden, H., Mielke S., Marx D., et al. (1997) Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations. Anticancer Res. 17(4B):3075–7.
Menge, T., Hartung, H. P., Stüve, O. (2005) Statins-a cure-all for the brain? Nat Rev Neurosci. 6(4):325–31.
Metz, L. M., Zhang, Y., Yeung, M., et al. (2004) Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 55(5):756.
Miller, D. H., Khan, O. A., Sheremata, W. A., et al. (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 348(1):15–23.
Monson, N. L., Cravens, P. D., Frohman, E. M., et al. (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 62(2):258–64.
Morini, M., Roccatagliata, L., Dell’Eva, R., et al. (2004) Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148(1–2):146–153.
Muller, H., Hofer, S., Kaneider, N., et al. (2005) The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur. J. Immunol. 35(2):533–545.
Multiple Sclerosis Study Group. (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann. Neurol. 27(6):591–605.
Nakajima, A., Yamanaka, H., Kamatani, N. (2003) Leflunomide: clinical effectiveness and mechanism of action. Clin. Calcium 13(6):771–775.
Neuhaus, O., Strasser-Fuchs, S., Fazekas, F., et al. (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59(7):990–997.
Nicholson, L. B., Greer, J. M., Sobel, R. A., et al. (1995) An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3(4):397–405.
Niino, M., Kikuchi, S., Fukazawa, T., et al. (2001) Genetic polymorphisms of IL-1beta and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. J. Neuroimmunol. 118(2):295–299.
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., Weinshenker, B. G. (2000a) Multiple sclerosis. N. Engl. J. Med. 343:938–952.
Noseworthy, J. H., Wolinsky, J. S., Lublin, F. D., et al. (2000b) Linomide in relapsing and secondary progressive MS. I. Trial design and clinical results; North American Linomide Investigators. Neurology 2000;54(9):1726–1733.
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., Weinshenker, B. G. (2001) Multiple Sclerosis. N. Engl. J. Med. 343(13):938–952.
O’Connor, P. W., Li, D., Freedman, M. S., et al. (2006a) Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group: a phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66(6):894–900.
O’Connor, P., Antel, J., Comi, G. (2006b) Oral FTY720 in relapsing MS: results of the dose-blinded, active drug extension phase of a phase II study. Neurology 66(Suppl. 5):A123.
Omari, K. M., John, G. R., Sealfon, S. C., Raine, C. S. (2005) CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 128(Pt 5):1003–1015.
Omari, K. M., John, G., Lango, R., Raine, C. S. (2006) Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 53(1):24–31.
Paemen, L., Martens, E., Norga, K., et al. (1996) The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem. Pharmacol. 52(1):105–111.
Paintlia, A. S., Paintlia, M. K., Khan, M., et al. (2005) HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J. 19(11):1407–1421.
Palace, J., Rothwell, P. (1997) New treatments and azathioprine in multiple sclerosis. Lancet 350(9073):261.
Panitch, H., Francis, G., Oral Myelin Study Group. (1997) Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis [abstract]. Ann. Neurol. 42:459.
Paolillo, A., Coles, A. J., Molyneux, P. D., et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53(4):751–757.
Patti, F., Amato, M. P., Filippi, M., et al. (2004) A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J. Neurol. Sci. 223(1):69–71.
Pershadsingh, H. A. (2004) Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin. Invest. Drugs 13(3): 215–228.
Pershadsingh, H. A., Heneka, M. T., Saini, R., et al. (2004) Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J. Neuroinflamm. 1(1):3.
Petereit, H. F., Rubbert, A. (2005) Effective suppression of cerebrospinal fluid B cells by rituximab and cyclophosphamide in progressive multiple sclerosis. Arch. Neurol. 62(10):1641–1642; author reply 1642.
Polman, C., Barkhof, F., Sandberg-Wollheim, M., et al. (2005) Laquinimod in Relapsing MS Study Group: Treatment with laquinimod reduces development of active I lesions in relapsing MS. Neurology 64(6):987–991.
Polman, C. H., O’Connor, P. W., Havrdova, E., et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9):899–910.
Popovic, N., Schubart, A., Goetz, B. D., et al. (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol. 51(2):215–223.
Ramtahal, J., Jacob, A., Das, K., Boggild, M. (2005) 5-Year retrospective study of the use of mitoxantrone and glatiramer acetate combination in Patients with very active relapsing remitting multiple sclerosis. Neurology 4(Suppl. 1):A386–387, P06.163.
Ransohoff, R. M. (1999) Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J. Neuroimmunol. 98(1):57–68.
Ransohoff, R. M. (2005) Natalizumab and PML. Nat. Neurosci. 8(10):1275.
Rausch, M., Hiestand, P., Foster, C. A., et al. (2004) Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 20(1):16–24.
Reggio, E., Nicoletti, A., Fiorilla, T. (2005) The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients: twenty-four months follow-up. J. Neurol. 252(10):1255–1261.
Rice, G. P., Filippi M., Comi G. (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial: Cladribine MRI Study Group. Neurology 14;54(5):1145–1155.
Rice G. P, Hartung, H. P., Calabresi, P. A. (2005) Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 64(8):1336–1342.
Rizvi, S. A., Bashir, K. (2004) Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 63(Suppl. 6):S47–S54.
Romine, J. S., Sipe, J. C., Koziol, J. A., et al. (1999) A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians 111(1):35–44.
Rose, J. W., Watt, H. E., White, A. T., Carlson, N. G. (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56(6): 864–867.
Rosen, H., Goetzl, E.J (2005) Spingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5(7):560–570.
Rudick, R. A., Stuart, W. H., Calabresi, P. A., et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354(9):911–923.
Rumbach, L., Racadot, E., Armspach, J. P., et al. (1996) Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. Mult. Scler. 1(4):207–212.
Runstrom, A., Leanderson, T., Ohlsson, L., Axelsson, B. (2006) Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J. Neuroimmunol. 173(1–2):69–78.
Sakaguchi, S. (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6(4):345–352.
Salomon, B., Bluestone, J. A. (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225–252.
Scheinfeld, N. (2006) Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin. Drug Saf. 5(2):197–209.
Schimrigk, K., Brune, N., Hellwig, K., et al. (2005) An open-label, prospective study of oral fumaric acid therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). Neurology. 64(Suppl. 1):A392, S46.003.
Scolding, N. (2005) Devic’s disease and autoantibodies. Lancet Neurol. 4(3):136–137.
Scott, G. S., Spitsin, S. V., Kean, R. B., et al. (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc. Natl. Acad. Sci. U S A. 99(25):16303–16308.
Sehgal, S. N. (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 35(Suppl):7S–14S.
Sellebjerg, F., Sorensen, T. L. (2003) Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res. Bull. 61(3):347–355.
Serkova, N. J., Christians, U., Benet, L. Z. (2004) Biochemical mechanisms of cyclosporine neurotoxicity. Mol. Interv. 4(2):97–107.
Sette, A., Alexander, J., Ruppert, J., et al. (1994) Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu. Rev. Immunol. 12:413–431.
Sharpe, A. H., Freeman, G. J. (2002) The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2):116–126.
Sicotte, N. L., Liva, S. M., Klutch, R., et al. (2002) Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52(4):421–428.
Sicotte, N. L., Giesser, B. S., Tandon, V. (2006) A pilot study of testosterone treatment for men with relapsing remitting multiple sclerosis. Neurology 66(Suppl.):A30–A30.
Sidiropoulos, P. I., Boumpas, D. T. (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13(5):391–397.
Simmons, D. L., Buckley, C. D. (2005) Some new, and not so new, anti-inflammatory targets. Curr. Opin. Pharmacol. 5(4):394–397.
Sipe, J. C. (2005) Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother. 5(6):721–727.
Sipe, J. C., Romine, J. S., Koziol, J. A., et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344(8914):9–13.
Sipe, J. C., Romine, J. S., Koziol, J., et al. (1997) Cladribine improves relapsing-remitting MS: a double blind placebo controlled study. Neurology 48(Suppl. 2):A340.
Sjöö, F., Hassan Z., Abedi-Valugerdi, M., et al. (2006) Myeloablative and immunosuppressive properties of treosulfan in mice. Exp. Hematol. 34(1):115–121.
Smilek, D. E., Wraith, D. C., Hodgkinson, S., et al. (1991). A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U S A 88(21):9633–9637.
Smolen, J. S., Emery, P., Kalden, J. R., et al. (2004) The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J. Rheumatol. Suppl. 71:13–20.
Sommer, N., Loschmann, P. A., Northoff, G. H., et al. (1995) The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1(3):244–248.
Sorensen, T. L., Tani, M., Jensen, J., et al. (1999). Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103(6):807–815.
Sorensen, T. L., Trebst, C., Kivisakk, P., et al. (2002) Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 127(1–2):59–68.
Sospedra, M., Martin, R. (2005a) Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683–747.
Sospedra, M., Martin, R. (2005b) Antigen-specific therapies in multiple sclerosis. Int. Rev. Immunol. 24(5–6):393–413.
Steinman, L. (2001) Multiple sclerosis: a two-stage disease. Nat. Immunol. 2:762–764.
Steinman, L. (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4(6):510–518.
Steinman, L., Zamvil, S. S. (2005) Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26(11):565–571.
Storer, P. D, Xu, J., Chavis, J., Drew, P. D. (2005). Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J. Neuroimmunol. 161(1–2):113–122.
Stuart, R. W., Racke, M. K. (2002) Targeting T cell costimulation in autoimmune disease. Expert Opin. Ther. Targets. 6(3):275–289.
Stüve, O., Cepok, S., Elias, B., et al. (2005) Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol. 62(10):1620–1623.
Stüve, O., Youssef, S., Weber, M.S., et al. (2006) Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J. Clin. Invest. 116:1037–1044.
Swain, S. M. (1998) Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin. Oncol. 25(Suppl. 10):43–47.
Tubridy, N., Behan, P. O., Capildeo, R., et al. (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS; the UK Antegren Study Group. Neurology 53(3):466–472.
Ubogu, E. E., Cossoy, M. B., Ransohoff, R. M. (2005) The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol. Sci. 27(1):48–55.
Utset, T. O., Auger, J. A., Peace, D., et al. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J. Rheumatol. 29(9):1907–1913.
Van Assche, G., Van Ranst, M., Sciot, R., et al. (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 353(4): 362–368.
Van Oosten, B. W., Uitdehaag, B. M., Barkhof, F., et al. (1997) Interleukin-2 therapy does not exacerbate multiple sclerosis. Neurology 49(2):633–634.
Vermersch, P., Waucquier, N., Bourteel, H., et al. (2004) Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenolate mofetil (Cellcept): results of a phase II clinical trial. Neurology 62(Suppl.):A259–A259.
Viglietta, V., Baecher-Allan, C., Weiner, H. L., Hafler, D. A. (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199(7):971–979.
Vincenti, F., Kirkman, R., Light, S., et al. (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338(3):161–165.
Vollmer, T., Key, L., Durkalski, V., et al. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363(9421):1607–1608.
Waldmann, H. (1989) Manipulation of T-cell responses with monoclonal antibodies. Annu. Rev. Immunol. 7:407–444.
Warren, K. G., Catz, I., Wucherpfennig, K. W. (1997) Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci. 152(1):31–38.
Webb, M., Tham, C. S., Lin, F. F., et al. (2004) Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 153(1–2):108–121.
Weber, M. S., Prod’homme, T., Steinman, L., Zamvil, S. S. (2005) Drug Insight: using statins to treat neuroinflammatory disease. Nat. Clin. Pract. Neurol. 1:106–112.
Wei, S. H., Rosen, H., Matheu, M. P., et al. (2005) Shingosine-1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat. Immunol. 6(12):1228–1235.
Weiner, H. L., Cohen, J. A. (2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult. Scler. 8(2):142–154.
Weiner, H. L., Mackin, G. A., Matsui, M., et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259(5099):1321–1324.
Weinshenker, B. G., Bass, B., Karlik, S., et al. (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41(7):1047–1052.
Weissert, R., Wiendl, H., Pfrommer, H., et al. (2003) Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. J. Neuroimmunol. 144(1–2):28–37.
Wiendl, H., Hohlfeld, R. (2002). Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Biodrugs 16(3):183–200.
Wiendl, H., Hohlfeld, R. (2006) Cytokine-based therapeutics for intrinsic CNS disease processes. In Ransohoff R. M., Benveniste E. N. (Eds): Cytokines and the CNS, Taylor & Francis, 2nd Edition, 328–351.
Wiendl, H., Kieseier, B. C., Weissert, R., et al. (2005) Treatment of active secondary progressive multiple sclerosis with treosulfan: an open label pilot study. Mult. Scler. 11(Suppl.1):181, P680.
Willenborg, D. O., Fordham, S., Bernard, C. C., et al. (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157(8):3223–3227.
Wingerchuk, D. M., Weinshenker, B. G. (2005) Neuromyelitis optica. Curr. Treat. Options Neurol. 7(3):173–182.
Yadav, V., Marracci, G., Lovera, J., et al. (2005) Lipoic acid in multiple sclerosis: a pilot study. Mult. Scler. 11(2):159–165.
Yang, J. S., Xu, L. Y., Xiao, B. G., et al. (2004) Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol. 156(1–2):3–9.
Yong, V. W. (2005). Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat. Rev. Neurosci. 6(12):931–944.
Yong, V. W., Wells, J., Giuliani, F., et al. (2004) The promise of minocycline in neurology. Lancet Neurol. 3(12):744–751.
Yopp, A. C., Fu, S., Honig, S. M., et al. (2004) FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J. Immunol. 173(2):855–865.
Yousry, T. A., Major, E. O., Ryschkewitsch, C., et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9):924–933.
Youssef, S., Stuve, O., Patarroyo, J. C., et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420(6911):78–84.
Yudkin, P. L., Ellison, G. W., Ghezzi, A., et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338(8774):1051–1055.
Zhao, G. J., Li, D. K., Wolinsky, J. S., et al. (1997) Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis; the MS Study Group. J. Neuroimaging 7(1):1–7.
Zipp, F., Krammer, P. H., Weller, M. (1999) Immune (dys) regulation in multiple sclerosis: role of the CD95-CD95 ligand system. Immunol. Today 20:550–554.
Zipp, F., Hartung, H. P., Hillert, J., et al. (2005). Blockade of chemokine receptor in multiple sclerosis patients. Mult. Scler. 11(Suppl. 1):S13.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Wiendl, H., Hohlfeld, R. (2007). Review of Novel Immunotherapeutic Strategies for MS. In: Zhang, J. (eds) Immune Regulation and Immunotherapy in Autoimmune Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-36003-4_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-36003-4_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-36002-7
Online ISBN: 978-0-387-36003-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)